Thomas Lingelbach
Chief Executive Officer chez VALNEVA
Fortune : 2 M $ au 31/03/2024
Profil
Thomas Lingelbach is currently the President, Chief Executive Officer & Director at Valneva SE since 2023.
He is also the President & Chief Executive Officer at Intercell Austria AG since 2013, the Chief Executive Officer at Grätzelmixer GmbH since 2017, the President, Chief Executive Officer & Director at Valneva USA, Inc. since 2008, the Chairman at Vaccines Holdings Sweden AB since 2014, the Chairman at Valneva Sweden AB since 2015, the Director at Valneva Scotland Ltd.
since 2006, the Co-Managing Director at VALNEVA.
Austria GmbH since 2013, the Director at Valneva UK Ltd.
since 2015, and the Director at Valneva Canada, Inc. since 2015.
Previously, he was the President & Chief Executive Officer at Intercell AG from 2006 to 2013, the President, Chief Executive Officer & Director at Intercell USA, Inc., the Chief Executive Officer at Elatos GmbH from 2013 to 2015, the Managing Director & General Manager at GSK Vaccines GmbH, and the Managing Director at Chiron Behring Gmbh & Co. Kg.
He also served as the VP-Vaccines Global Industrial Operations at Chiron Corp.
from 1997 to 2005.
Dr. Lingelbach graduated from Technische Hochschule Mittelhessen.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
VALNEVA SE
0,28% | 31/12/2023 | 385 545 ( 0,28% ) | 2 M $ | 31/03/2024 |
Postes actifs de Thomas Lingelbach
Sociétés | Poste | Début |
---|---|---|
VALNEVA | Chief Executive Officer | - |
Valneva Canada, Inc.
Valneva Canada, Inc. Medical DistributorsDistribution Services Part of Valneva SE, Valneva Canada, Inc. engages in marketing and distribution of vaccines. The private company is based in Kirkland, Canada. | Director/Board Member | 01/01/2015 |
Valneva USA, Inc. | Chief Executive Officer | 01/11/2011 |
Grätzelmixer GmbH | Chief Executive Officer | 01/09/2017 |
Intercell Austria AG | Chief Executive Officer | 01/01/2013 |
Valneva Sweden AB
Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | Chairman | 01/02/2015 |
Valneva Scotland Ltd.
Valneva Scotland Ltd. BiotechnologyHealth Technology Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers. | Director/Board Member | 01/12/2006 |
Valneva UK Ltd.
Valneva UK Ltd. Medical/Nursing ServicesHealth Services Part of Valneva SE, Valneva UK Ltd. provides health care services. The private company is based in London, UK and was founded in 2015. | Director/Board Member | 19/10/2015 |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Chairman | 01/12/2014 |
░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Thomas Lingelbach
Sociétés | Poste | Fin |
---|---|---|
░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Formation de Thomas Lingelbach
Technische Hochschule Mittelhessen | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
VALNEVA | Health Technology |
Entreprise privées | 14 |
---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Intercell USA, Inc.
Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Valneva Scotland Ltd.
Valneva Scotland Ltd. BiotechnologyHealth Technology Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers. | Health Technology |
GSK Vaccines GmbH
GSK Vaccines GmbH Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GSK Vaccines GmbH is a German company that manufactures and distributes pharmaceutical products. The private company is based in Marburg, Germany. The company was founded in 2009. Christopher Hunley has been the CEO of the company since 2020. | Health Technology |
Valneva Austria GmbH
Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Commercial Services |
Elatos GmbH | |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Health Technology |
Valneva Sweden AB
Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | Health Technology |
Intercell Austria AG | |
Valneva UK Ltd.
Valneva UK Ltd. Medical/Nursing ServicesHealth Services Part of Valneva SE, Valneva UK Ltd. provides health care services. The private company is based in London, UK and was founded in 2015. | Health Services |
Valneva Canada, Inc.
Valneva Canada, Inc. Medical DistributorsDistribution Services Part of Valneva SE, Valneva Canada, Inc. engages in marketing and distribution of vaccines. The private company is based in Kirkland, Canada. | Distribution Services |
Grätzelmixer GmbH | |
Valneva USA, Inc. |